Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis S Sawcer, G Hellenthal, M Pirinen, CC Spencer, NA Patsopoulos, ... | 3042* | 2011 |
Imaging biomarker roadmap for cancer studies JPB O'Connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ... Nature reviews Clinical oncology 14 (3), 169-186, 2017 | 1095 | 2017 |
Adaptive designs in clinical trials: why use them, and how to run and report them P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ... BMC medicine 16 (1), 1-15, 2018 | 649 | 2018 |
Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges SS Villar, J Bowden, J Wason Statistical Science 30 (2), 199-215, 2015 | 462 | 2015 |
Imaging breast cancer using hyperpolarized carbon-13 MRI FA Gallagher, R Woitek, MA McLean, AB Gill, R Manzano Garcia, ... Proceedings of the National Academy of Sciences 117 (4), 2092-2098, 2020 | 189 | 2020 |
Correcting for multiple-testing in multi-arm trials: is it necessary and is it done? JMS Wason, L Stecher, AP Mander Trials 15 (1), 1-7, 2014 | 174 | 2014 |
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor M Ban, A Goris, ÅR Lorentzen, A Baker, T Mihalova, G Ingram, DR Booth, ... European journal of human genetics 17 (10), 1309-1313, 2009 | 158 | 2009 |
Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process MD Witham, E Anderson, C Carroll, PM Dark, K Down, AS Hall, J Knee, ... Trials 21 (1), 1-9, 2020 | 146 | 2020 |
The Adaptive designs CONSORT Extension (ACE) Statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design M Dimairo, P Pallmann, J Wason, S Todd, T Jaki, SA Julious, AP Mander, ... BMJ, 2019 | 134 | 2019 |
A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials J Wason, L Trippa Statistics in medicine 33 (13), 2206-2221, 2014 | 121 | 2014 |
Optimal design of multi‐arm multi‐stage trials J Wason, T Jaki Statistics in Medicine 31 (30), 4269-4279, 2012 | 121 | 2012 |
Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a pragmatic, randomised controlled, superiority trial P Fonagy, S Butler, D Cottrell, S Scott, S Pilling, I Eisler, P Fuggle, ... The Lancet Psychiatry, 2018 | 119 | 2018 |
Some recommendations for multi-arm multi-stage trials J Wason, D Magirr, M Law, T Jaki Statistical methods in medical research 25 (2), 716-727, 2016 | 109 | 2016 |
The effect of sleep deprivation and exercise on reaction threshold in peanut-allergic adults: a randomised controlled study S Dua, M Ruiz-Garcia, S Bond, SR Durham, I Kimber, C Mills, G Roberts, ... Journal of Allergy and Clinical Immunology, 2019 | 103* | 2019 |
Stepped wedge cluster randomized controlled trial designs: a review of reporting quality and design features MJ Grayling, JMS Wason, AP Mander Trials 18, 1-13, 2017 | 82 | 2017 |
Confounding underlies the apparent month of birth effect in multiple sclerosis B Fiddes, J Wason, A Kemppinen, M Ban, A Compston, S Sawcer Annals of neurology 73 (6), 714-720, 2013 | 82 | 2013 |
Simple MRI score aids prediction of dementia in cerebral small vessel disease AA Al Olama, JMS Wason, AM Tuladhar, EMC van Leijsen, M Koini, ... Neurology 94 (12), e1294-e1302, 2020 | 77 | 2020 |
Efficient adaptive designs for clinical trials of interventions for COVID-19 N Stallard, L Hampson, N Benda, W Brannath, T Burnett, T Friede, ... Statistics in Biopharmaceutical Research 12 (4), 483-497, 2020 | 72 | 2020 |
Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc … EL Gerety, EM Lawrence, J Wason, H Yan, S Hilborne, J Buscombe, ... Annals of Oncology 26 (10), 2113-2118, 2015 | 72 | 2015 |
When to keep it simple–adaptive designs are not always useful JMS Wason, P Brocklehurst, C Yap BMC Medicine 17 (1), 1-7, 2019 | 71 | 2019 |